Orca Wealth Management LLC Makes New $4.53 Million Investment in AstraZeneca PLC (NASDAQ:AZN)

Orca Wealth Management LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 69,166 shares of the company’s stock, valued at approximately $4,532,000. AstraZeneca makes up about 4.1% of Orca Wealth Management LLC’s holdings, making the stock its 5th largest position.

Other large investors also recently bought and sold shares of the company. Martin Investment Management LLC grew its stake in shares of AstraZeneca by 2.8% during the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after purchasing an additional 7,615 shares during the period. Nordea Investment Management AB acquired a new position in shares of AstraZeneca during the 4th quarter worth $754,000. Diversify Wealth Management LLC grew its stake in shares of AstraZeneca by 3.6% during the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after purchasing an additional 153 shares during the period. Ameritas Advisory Services LLC grew its stake in shares of AstraZeneca by 25.9% during the 4th quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company’s stock worth $622,000 after purchasing an additional 1,949 shares during the period. Finally, Integrated Advisors Network LLC grew its stake in AstraZeneca by 46.6% in the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after acquiring an additional 13,860 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

AZN has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Price Performance

AstraZeneca stock opened at $69.59 on Wednesday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The stock has a market capitalization of $215.80 billion, a P/E ratio of 33.30, a P/E/G ratio of 1.13 and a beta of 0.46. The firm’s 50-day moving average is $66.58 and its two-hundred day moving average is $74.08. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s revenue was up 18.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.87 EPS. Equities analysts predict that AstraZeneca PLC will post 4.12 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.